A Phase 3 interventional study of Sodium Zirconium Cyclosilicate in Hyperkalemia, sponsored by ZS Pharma, Inc.. Completed at 51 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-27.
Sponsored by ZS Pharma, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 3rd largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 3rd registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2014; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 751 is above the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 120 across the 27 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under ZS Pharma, Inc., one of the names counted as AstraZeneca. Under that name alone:
ZS Pharma, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
39 studies in Hyperkalemia by AstraZeneca: 2 open now, 3 under way, 1 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2014, is one of 13 in phase 3, and was the 6th registered.
AstraZeneca’s Hyperkalemia studies by the year they started, since 2011.
2 of the studies testing sodium zirconium cyclosilicate in Hyperkalemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736184Qianfoshan HospitalThe Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | 2026-12-31 |
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, from their registry updates:
Among AstraZeneca’s 39 in Hyperkalemia:
This tab as a report to print or save as PDF → With an account.
The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase.
Subjects with 2 consecutive i STAT potassium values 5.1 mmol/L will enter the Acute Phase and receive ZS 10 g tid for 24 to 72 hours, depending on potassium values. Once normokalemia (i STAT potassium between 3.5 and 5.0 mmol/L, inclusive) is restored (whether after 24, 48 or 72 hours), subjects will be enrolled in the Maintenance Phase to be dosed with ZS at a starting dose of 5 g qd. Potassium (i STAT and central laboratory) will be measured weekly throughout the first month of study and every 4 weeks thereafter through Month 12. During the Maintenance Phase, the ZS dose may be increased or decreased in increments/decrements of 5 g qd up to a maximum of 15 g qd or a minimum of 5 g every other day based on i STAT potassium measurements as outlined below:
.• Between 3.0 and 3.4 mmol/L, inclusive: decrease ZS dose in 5 g qd decrements to a minimum dose of 5 g every other day; if a subject's i STAT potassium value remains between 3.0 and 3.4 mmol/L, inclusive, on the ZS 5 g every other day dose, the subject will be withdrawn from the study and receive standard of care treatment.
There is no limit to the number of dose titrations allowed. Subjects will receive up to 12 months of treatment with open-label ZS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sodium Zirconium Cyclosilicate
Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
Also known as: ZS
Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase
Percentage of subjects with S-K values between 3.5 and 5.0 mmol/L, inclusive at the end of the Acute Phase - ITT Population
Time frame: 72 Hours
Percentage of Participants With Mean S-K Values ≤ 5.1 mmol/L During Extended Dosing Phase Days 85 to 365
Percentage of subjects with mean S-K values ≤ 5.1 mmol/L during Extended Dosing Phase - ITT Population
Time frame: Study Days 85 to 365
Proportion of Subjects With Mean S-K Between 3.5 and 5.5 mmol/L, Inclusive Months 3 to 12
Proportion of Subjects with mean S-K between 3.5 and 5.5 mmol/L during Extended Dosing Phase - ITT Population
Time frame: Study Days 85 to 365
Mean S-K Levels Months 3 to 12, Months 6 to 9, and Months 9 to 12.
Mean S-K levels months 3 to 12(EP Days 85, 113, 141, 176, 211, 239, 267, 295, 330, 365 and EOS),months 6 to 9, and months 9 to 12.
Time frame: Study days 85 to 365
Participants took part in the study at 56 sites in the Unites States, Australia, South Africa, Germany, the United Kingdom and the Netherlands from 23 June 2014 to 04 November 2016
| Milestone | Subject Disposition |
|---|---|
| Started | 751 |
| Completed | 746 |
| Not completed | 5 |
| Withdrew: Participant's compliance | 1 |
| Withdrew: Hypo- or hyperkalemia | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Subject Disposition |
|---|---|
| Started | 746 |
| Completed | 466 |
| Not completed | 280 |
| Withdrew: Adverse event | 51 |
| Withdrew: Expected progression of ckd | 40 |
| Withdrew: Hypokalemia | 9 |
| Withdrew: Sponsor's decision | 5 |
| Withdrew: Met ecg withdrawal criteria | 7 |
| Withdrew: Withdrawal by subject | 81 |
| Withdrew: Physician decision | 8 |
| Withdrew: Lost to follow-up | 31 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Death | 8 |
| Withdrew: Subject compliance | 17 |
| Withdrew: Hyperkalemia | 5 |
| Withdrew: Various reasons | 16 |
Proportion of Subjects with mean S-K between 3.5 and 5.5 mmol/L during Extended Dosing Phase - ITT Population
| Proportion of participants | Proportion |
|---|---|
| Proportion of Subjects With Mean S-K Between 3.5 and 5.5 mmol/L, Inclusive Months 3 to 12 | 0.985 (0.972 to 0.993) |
Mean S-K levels months 3 to 12(EP Days 85, 113, 141, 176, 211, 239, 267, 295, 330, 365 and EOS),months 6 to 9, and months 9 to 12.
| mmol/L | Mean S-K Levels Months 3 to 12,6 to 9, and 9 to 12 |
|---|---|
| Acute Phase Baseline | 5.59 ± 0.425 |
| Extended Dosing Days 85 to 365/End of Study | 4.66 ± 0.379 |
| Extended Dosing Days 211 to 267 | 4.68 ± 0.404 |
| Extended Dosing Days 295 to 365 | 4.62 ± 0.401 |
Percentage of subjects with S-K values between 3.5 and 5.0 mmol/L, inclusive at the end of the Acute Phase - ITT Population
| Percentage of participants | Percentage |
|---|---|
| Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase | 77.9 (74.8 to 80.9) |
Percentage of subjects with mean S-K values ≤ 5.1 mmol/L during Extended Dosing Phase - ITT Population
| Percentage of participants | Percentage |
|---|---|
| Percentage of Participants With Mean S-K Values ≤ 5.1 mmol/L During Extended Dosing Phase Days 85 to 365 | 88.4 (85.7 to 90.8) |
Collected over One year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acute Phase: ZS | 0/751 (0%) | 1/751 (0.1%) | 11/751 (1.5%) |
| Extended Dosing Phase: ZS | 8/746 (1.1%) | 161/746 (21.6%) | 386/746 (51.7%) |
| Event | Acute Phase: ZS | Extended Dosing Phase: ZS |
|---|---|---|
| PneumoniaInfections and infestations | 0/751 | 14/746 |
| Cardiac failure congestiveCardiac disorders | 0/751 | 11/746 |
| Chest painGeneral disorders | 0/751 | 11/746 |
| OsteomyelitisInfections and infestations | 0/751 | 8/746 |
| Renal failure acuteRenal and urinary disorders | 0/751 | 8/746 |
| CellulitisInfections and infestations | 0/751 | 7/746 |
| Acute myocardial infarctionCardiac disorders | 0/751 | 6/746 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/751 | 5/746 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/751 | 5/746 |
| HypertensionVascular disorders | 0/751 | 4/746 |
| Event | Acute Phase: ZS | Extended Dosing Phase: ZS |
|---|---|---|
| HypertensionVascular disorders | 1/751 | 78/746 |
| Oedema peripheralGeneral disorders | 1/751 | 72/746 |
| NauseaGastrointestinal disorders | 4/751 | 56/746 |
| Urinary tract infectionInfections and infestations | 3/751 | 55/746 |
| ConstipationGastrointestinal disorders | 2/751 | 46/746 |
| AnaemiaBlood and lymphatic system disorders | 0/751 | 42/746 |
| Upper respiratory infectionInfections and infestations | 0/751 | 37/746 |
| Age, Continuous(Years) | Acute Phase: ZS |
|---|---|
| Mean | 63.6 ± 13.03 |
| Sex: Female, Male(Participants) | Acute Phase: ZS |
|---|---|
| Female | 303 |
| Male | 448 |
| Race/Ethnicity, Customized(Participants) | Acute Phase: ZS |
|---|---|
| Asian | 25 |
| Native Hawaiian or Other Pacific Islander | 3 |
| Black or African American | 89 |
| White | 624 |
| Other | 10 |
| Use of RAAS inhibitor medication(Participants) | Acute Phase: ZS |
|---|---|
| Count of participants | 527 |
| Co-morbidities at baseline(Participants) | Acute Phase: ZS |
|---|---|
| Diabetes mellitus | 471 |
| Chronic kidney disease | 513 |
| Heart Failure | 285 |
| Baseline eGFR(Participants) | Acute Phase: ZS |
|---|---|
| <15 | 46 |
| 15-<30 | 243 |
| 30-<60 | 263 |
| ≥60 | 190 |
| Missing | 9 |
| Acute Phase baseline Serum Potassium(Participants) | Acute Phase: ZS |
|---|---|
| <5.5 mmol/L | 287 |
| 5.5<6.0 mmol/L | 338 |
| ≥6.0 mmol/L | 126 |
Plan to share: No
Ran from Jun 2014 to primary completion in Nov 2016, 29 months.
Results were first posted in Jun 2018, 1 year 6 months after primary completion.
Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 29 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate